HIGHER:
- Broadsoft (Nasdaq: BSFT) 43% HIGHER; reports Q3 EPS of $0.08,
15 cents better than the analyst estimate of ($0.07). Revenue for
the quarter was $22.3 million, which compares to the estimate of
$19.60 million. For the fourth quarter of 2010, BroadSoft
anticipates revenue of $31.0 to $32.0 million (Consensus is
$30.17M) For the fourth quarter, the Company expects to achieve
earnings per share on a non-GAAP basis of $0.28 to $0.31 per
diluted share (Consensus is $0.29)
- American Public Education (Nasdaq: APEI) 21% HIGHER; reports
Q3 EPS of $0.30, 1 cent better than the analyst estimate of
$0.29. Revenue for the quarter was $48.3 million, which compares
to the estimate of $47.31 million. Sees Q4 EPS of 45-47c, vs. the
consensus of 44c. Sees net course registrations up 26-29%.
- Genomic Health (Nasdaq: GHDX) 16% HIGHER; reports Q3 EPS of
$0.12, 12 cents better than the analyst estimate of $0.00.
Revenue for the quarter was $46.3 million, which compares to the
estimate of $44.90 million.
- TechTarget (Nasdaq: TTGT) 15% HIGHER; reports Q3 EPS of
$0.05, ex-items, inline with the analyst estimate of $0.05.
Revenue for the quarter was $22 million, which compares to the
estimate of $22.76 million. Sees Q4 sales of $25.5-$26.5 million,
vs. the consensus of $25.6 million. Also announced 10 million
share buyback at $6/share.
- Priceline.com (Nasdaq: PCLN) 9% HIGHER; reports Q3 EPS of
$5.33, versus the analyst estimate of $4.97. Revenue for the
quarter was $1 billion, which compares to the estimate of $973.63
million. Sees Q410 EPS of $2.91 - $3.06, versus the consensus of
$2.68. sees Q410 sales up about 31 - 36% from Q409.
LOWER:
Metabolix (Nasdaq: MBLX) 20% LOWER; reports Q3 loss of $0.37, 2
cents worse than the analyst estimate of ($0.35). Revenue for the
quarter was $46,000, which compares to the estimate of $250,000.
- Dean Foods (
DF
) 16% LOWER; reports Q3 EPS of $0.13, ex-items, 8 cents lower
than the consensus of $0.21. Revenue for the quarter came in at
$3.1 billion, compared to the consensus of $3.04 billion. Sees Q4
adj-EPS of 13-18c, vs. the consensus of 27c.
- China Sky One Medical (Nasdaq: CSKI) 13% LOWER; reports Q3
adjusted EPS of $0.40, versus the consensus of $0.74. Revenue for
the quarter came in at $36.2 million, compared to the consensus
of $45.75 million. Reiterates FY10 outloo
- EnerNOC (Nasdaq: ENOC) 12% LOWER; reports Q3 EPS of $1.81,
vs. the analyst estimate of $1.56. Revenue for the quarter was
$162.8 million, which compares to the estimate of $160.81
million. Sees Q4 sales of $20-$24 million with a loss of 62-73c.
The Street is looking for Q4 sales of $29.41 million and a loss
of 65c.
- CardioNet (Nasdaq: BEAT) 12% LOWER; reports a Q3 loss of
$0.25, 20 cents worse than the analyst estimate of ($0.05).
Revenue for the quarter was $27.5 million, which compares to the
estimate of $32.04 million.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.